▶ A freelance English to Korean/Korean to English translator specializing in the fields of Medical, Environment, Chemical engineering, Food technology, Cosmetics etc.
▶ Available Programs: Wordfast, Trados, Smartcat, Memsource.
▶ Translation and Proofreading experience: 5 years.
<Clinical Protocols, ICF, IB, etc. >
| -A 1-year double-blind, triple-dummy, active comparator-controlled study evaluating tofacitinib 5 mg BID with and without MTX and adalimumab 40 mg subcutaneously every other week with MTX. |
| -A Combined Phase 2/3, Double-Blind, Randomized, Placebo-Controlled, Induction and Maintenance Study Evaluating the Safety and Efficacy of GS-5745 in Subjects with Moderately to Severely Active Ulcerative Colitis |
| -A multicenter, double-blind, placebo-controlled, randomized phase 3 trial with 1 planned IA, comparing gilteritinib as maintenance therapy versus placebo, in FLT3/ITD AML subjects in CR1. |
| -Comparable clinical efficacy, safety and immunogenicity of infliximab biosimilar (CT-P13) after transition from reference infliximab (Remicade®) in children with established inflammatory bowel disease: a multi-centre prospective observational |
| -A phase 1, first-in-human (FIH), open-label, multicenter, dose-escalation study of the safety, tolerability, activity and PK of REGN3767 administered as monotherapy and in combination with REGN2810 in patients with advanced malignancies. |
| -A Phase 3, Randomized, Double-Blind Study of Pembrolizumab (MK-3475) plus Epacadostat (INCB024360) Versus Pembrolizumab plus Placebo as First-Line Treatment in Patients with Metastatic Non-Small Cell Lung Cancer Expressing High Levels of PD-L1 |
| -Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Ertugliflozin Monotherapy in Subjects with Type 2 Diabetes Mellitus and Inadequate Glycemic Control Despite Diet and Exercise (MK-8835-003/B1521022) |
| -Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Ertugliflozin in Subjects with Type 2 Diabetes Mellitus and Inadequate Glycemic Control with Sitagliptin and Metformin (Study MK 8835-006/B1521015) |
| -Randomized Double-blind Factorial Study to Evaluate the Efficacy and Safety of the Combination of Ertugliflozin and Sitagliptin Compared with Ertugliflozin Alone and Sitagliptin Alone in Subjects with Type 2 Diabetes Mellitus and Inadequate Glycemic Control with Metformin Monotherapy (MK-8835-005/B1521019) |
| -Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of the Combination of Ertugliflozin and Sitagliptin in Subjects with Type 2 Diabetes Mellitus and Inadequate Glycemic Control with Diet and Exercise (MK-8835-017/B1521047) |
| -Randomized, Double-blind, Active Comparator-controlled Study to Evaluate the Efficacy and Safety of Addition of Ertugliflozin, Compared with Addition of Glimepiride, in Subjects with Type 2 Diabetes Mellitus and Inadequate Glycemic Control with Metformin (MK-8835-002/B1521013) |
| -Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Ertugliflozin in Subjects with Type 2 Diabetes Mellitus, Stage 3 Chronic Kidney Disease, and Inadequate Glycemic Control with Background Antihyperglycemic Therapy (MK-8835-001/B1521016) |
| -A Phase 2, Open Label, 2 Arm, Response Rate Study of Talazoparib in Men With DNA Repair Defects and Metastatic Castration Resistant Prostate Cancer Who Previously Received Taxane Based Chemotherapy and Progressed on at Least 1 Novel Hormonal -Agent (Enzalutamide and/or Abiraterone Acetate/Prednisone) |
| -A Phase 1, Open-Label, Dose-Escalation and Cohort Expansion First-in-Human Study of the Safety, Tolerability, Activity and Pharmacokinetics of REGN3767 (anti-LAG-3 mAb) Administered Alone or in Combination with REGN2810 (anti-PD-1 mAb) in Patients with Advanced Malignancies |
| -A randomized, placebo-controlled, single-blind single-ascending dose (SAD) phase in healthy subjects |
| -An open-label, multiple-ascending dose (MAD) phase in patients with moderate to severe hemophilia A or B without inhibitors |
| -An open-label, exploratory multiple dose (MD) phase in patients with moderate to severe hemophilia A or B without inhibitors |
| -An open-label MD phase in patients with moderate to severe hemophilia A or B with inhibitors |
| -A Phase 1/2 multicenter, multinational, 537open-label extension study to evaluate the long-term safety and efficacy of fitusiran in male patients with moderate or severe hemophilia A or B, with or without inhibitors, who previously tolerated dosing in Study ALN AT3SC 001 |
| -A Randomized, Open-Label, Phase 3 Study to Assess the Efficacy and Safety of KRN23 Versus Oral Phosphate and Active Vitamin D Treatment in Pediatric Patients with X- linked Hypophosphatemia (XLH) |
| -A PHASE I, OPEN-LABEL STUDY EVALUATING THE SAFETY, TOLERABILITY, AND PHARMACOKINETICS OF ESCALATING DOSES OF DHES0815A IN PATIENTS WITH HER2 POSITIVE BREAST CANCER |
| -A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study with Open-Label Extension to Assess the Efficacy and Safety of KRN23 in Adults with X-linked Hypophosphatemia (XLH) |
| -A Multicenter, Double-Blind, Randomized, Parallel-Group Study to Assess the Efficacy and Safety of MYL-1402O Compared with Avastin®, in the First-line Treatment of Patients with Stage IV Non-Squamous Non-Small Cell Lung Cancer |
| -An Exploratory Tumor Biopsy-Driven Study To Understand The Relationship Between Biomarkers and Indicators of Clinical Response in Immunomodulatory Treatment-Naïve Unresectable Stage III/IV Melanoma Patients Receiving REGN2810 (Anti-PD-1) |
| -etc. |
< Company info documents >
- Biocore. Co. Product information document (K→E)
- JW Holdings. Product development strategy (K→E)
- Meditox Co. Botulinum product information document (K→E)
-LG Lifescience. Medical device information document (Elavie Injection) (K→E)
-ConvaTech U.S. Customer information document (K→E)
-Pangen Biotech. Material Specification Sheet (K→E)
-California Almond Brochure (E→K)
-IOPcorporate Medical Device Manual(E →K)
-Valeo Inc. Antitrust Compliance (E →K)
-Corestem Standard Operation Process for Biological procedures (K→E)
-Washington Department of Health Code of Conduct(E →K)
-Molina Healthcare ‘Medicare and Medicaid’ Brochure(E →K)
-Advanced Instrument, ‘Anoxomat-III’ User Guide(E →K)
-Neulasta ‘On body’ Brochure(E →K)
-Company info clip subtitle (E→K), (E →K)
-Exoplan implant product(E →K)
-MicroVention Occulsion Balloon Catheter Brochure(E →K)
-Hysteroscopic tissue removal system(E →K)
-Instruction leaflet for SAVARA PHARMACEUTICALS Study(E →K)
- U.S. Department of Health and Human Services, Notice of Health Information Practices(E →K)
-3M Form dressing Manual(E →K)
-3M Critical and Chronic Care Solutions Division Introduction(E →K)
-Bristol-Myers Squibb ICF(E →K)
-Alianz insurance info(E →K)
-BBC Inc. Formats Delivery Specifications Contract (E →K)
-Fairfax vote info (E →K)
-KB stocks (K→E)
-DLM Co., Ltd, Company info (K→E)
-Keumho environment Co., Ltd, Company info (K→E)
-FDA Import Operation Manual (E →K)
-etc.
< Research articles >
- Science, Technology & Innovation Policy Report (STEPI) (E→K)
- Key Trends in CO2 Emissions thesis (E→K)
- Regulatory Impact Analysis for the Proposed Standards of Performance for Greenhouse Gas Emissions for New Stationary Sources: Electric Utility Generating Units (U.S. EPA) (E→K)
- Synthesis report on the aggregate effect of the intended nationally determined contributions(UN) (E→K)
- Modeling the flows of engineered nanomaterials during waste handling Article (E→K)
- The Korean Society of Anesthesiologists Homepage (K→E)
- VDT (Video Display Terminal) thesis (K→E)
- The correlation between stress levels and the actual consumption of sugar in female university students article (K→E)
- Biological and genetic characteristics of multidrug-resistant Enterobacter cloacae (K→E)
- Study on the field application of the analysis method for pesticide residues in ginseng (K→E)
- etc.
Portfolio